[June 20, 2016]

Unlocking High-Potential Reservoirs Will Drive Exponential Cancer Revenue Growth - Research and Markets

Research and Markets has announced the addition of the "Cancer Drug News Issue 671" report to their offering.

Cancer care is at a pivotal moment. 2015 big pharma oncology revenues benefited considerably from innovative products targeting underserved cancers. Whilst a great deal of commercial value has already been unlocked, the maturation of late-stage pipelines that includes a comprehensive catalogue of combinations will lead to exponential growth in the mid-term. With an increased focus on drug prices, premium oncology agents and combinations will continue to draw criticism, but pricing change will involve a multi-faceted and lengthy approach. Cost savings through lower-risk, more productive, novel innovation approaches are laying the foundations for long-term growth.

Key Topics Covered:

1. Breast Cancer

• FDA Approves New Indication For Faslodex
• Poziotinib Phase II rial Initiated In Advanced BC

• Onconova Receives Rigosertib Deal Termination Notice From Baxalta
• Amgen Submits Blincyto sBLA To FDA
• EMA (News - Alert) Grants ODD To Venetoclax In AML; Recommends Giotrif In Advance SCC

3. Lung Cancer

• AstraZeneca Faces Challenges In Navigating Transitional Period

4. Genito-Urinary Cancer

• Eusa/Aveo Seek EU Marketing Approval For Tivozanib In Advanced RCC

5. Gynaecological Cancer

• Combination Trial Of Avelumab/VS-6063 Initiated In Ovarian Cancer

6. Gastrointestinal Cancer

• Debiopharm Sees Victory In Japanese Oxaliplatin Lawsuit

7. Melanoma/Skin Cancer

• Ono Gains Japanese Approval For Partial Change In Opdivo Labelling

8. General Developments

• Yondelis Approved for Sale In Six Additional Countries
• Merck Enters Oncology Research Collaboration With EMBL
• Exelixis/Ipsen Enter Cabozantinib Licensing Deal
• Eisai's Halaven Approved In Japan To Treat STS
• Precision Medicine Development Driven By Big Data
• Baxalta Building Immuno-Oncology Capabilities

9. Supportive Therapies

• Specialized Therapeutics/Mundipharma Enter Sublicensing Deal For Anti-Emetic Products

For more information visit http://www.researchandmarkets.com/research/f5f6jm/cancer_drug_news

View source version on businesswire.com: http://www.businesswire.com/news/home/20160620005677/en/

[ Back To TMCnet.com's Homepage ]